阿哌沙班对比华法林在极端体重房颤患者中的疗效与安全性
该研究为ARISTOTLE试验的事后分析,纳入18 139例有体重和结局数据的房颤患者,按体重分为≤60 kg、>60-120 kg和>120 kg三组,评估阿哌沙班对比华法林的效果。结果显示,阿哌沙班在全部体重范围内疗效一致,且大出血风险均低于华法林,低体重组相对风险下降更明显。
要点
- 阿哌沙班在≤60 kg和>120 kg房颤患者中疗效与华法林一致。
- 阿哌沙班大出血风险在所有体重组均低于华法林。
- 低体重组(≤60 kg)大出血风险下降更显著(HR 0.55)。
核心结论
- 阿哌沙班在房颤患者中跨体重范围(包括低体重和高体重)有效且安全。
- 阿哌沙班相比华法林在疗效和安全性上的优势在各体重组中持续存在。
研究设计与样本
- ARISTOTLE试验的事后分析,随机对照试验,共18 201例,其中18 139例有体重和结局数据。
- 按体重分层(≤60 kg、>60-120 kg、>120 kg),使用Cox回归模型估计治疗效应并检验交互作用。
主要发现
- 低体重组(≤60 kg)1985例(10.9%),中间体重组(>60-120 kg)15 172例(83.6%),高体重组(>120 kg)982例(5.4%)。
- 卒中/系统性栓塞、全因死亡或心肌梗死的疗效终点在各体重组间一致(交互P值>0.05)。
- 大出血方面,阿哌沙班在所有体重组均优于华法林,低体重组HR 0.55(95% CI 0.36-0.82),中间体重组HR 0.71(95% CI 0.61-0.83),交互P值=0.016。
临床怎么用
- 房颤患者使用阿哌沙班抗凝可不考虑体重因素,包括低体重(≤60 kg)和高体重(>120 kg)患者。
- 低至正常体重患者使用阿哌沙班相比华法林的大出血风险下降可能更明显。
局限性
- 为事后分析,非预设亚组分析。
- 极端体重组样本量较小(高体重组仅982例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines caution against the use of non-vitamin K antagonist oral anticoagulants in patients with extremely high (>120 kg) or low (≤60 kg) body weight because of a lack of data in these populations. METHODS: In a post hoc analysis of ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; n=18 201), a randomized trial comparing apixaban with warfarin for the prevention of stroke in patients with atrial fibrillation, we estimated the randomized treatment effect (apixaban versus warfarin) stratified by body weight (≤60, >60-120, >120 kg) using a Cox regression model and tested the interaction between body weight and randomized treatment. The primary efficacy and safety outcomes were stroke or systemic embolism and major bleeding. RESULTS: Of the 18 139 patients with available weight and outcomes data, 1985 (10.9%) were in the low-weight group (≤60 kg), 15 172 (83.6%) were in the midrange weight group (>60-120 kg), and 982 (5.4%) were in the high-weight group (>120 kg). The treatment effect of apixaban versus warfarin for the efficacy outcomes of stroke/systemic embolism, all-cause death, or myocardial infarction was consistent across the weight spectrum (interaction P value>0.05). For major bleeding, apixaban had a better safety profile than warfarin in all weight categories and even showed a greater relative risk reduction in patients in the low (≤60 kg; HR, 0.55; 95% CI, 0.36-0.82) and midrange (>60-120 kg) weight groups (HR, 0.71; 95% CI, 0.61-0.83; interaction P value=0.016). CONCLUSIONS: Our findings provide evidence that apixaban is efficacious and safe across the spectrum of weight, including in low- (≤60 kg) and high-weight patients (>120 kg). The superiority on efficacy and safety outcomes of apixaban compared with warfarin persists across weight groups, with even greater reductions in major bleeding in patients with atrial fibrillation with low to normal weight as compared with high weight. The superiority of apixaban over warfarin in regard to efficacy and safety for stroke prevention seems to be similar in patients with atrial fibrillation across the spectrum of weight, including in low- and very high-weight patients. Thus, apixaban appears to be appropriate for patients with atrial fibrillation irrespective of body weight. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00412984.
引用
- Hohnloser SH, Fudim M, Alexander JH, et al. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. Circulation. 2019. PMID: 30773022. doi:10.1161/CIRCULATIONAHA.118.037955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。